London, UK,
17
September
2015
|
07:00
Europe/London

Amec Foster Wheeler wins radiochemical testing projects from CERN

Summary

Laboratory exceeds expectations with work on components from high energy accelerators

Amec Foster Wheeler announces today the award of a series of contracts from CERN, the European Organisation for Nuclear Research, to carry out radiochemical testing.

The work, which began earlier this year and is ongoing, involves characterisation of waste components taken from high energy accelerators including the Large Hadron Collider (LHC), the world’s largest particle accelerator.

Samples are sent from CERN’s headquarters near Geneva for analysis at Amec Foster Wheeler’s laboratories.

 

 

Greg Willetts, Consultancy Director of Amec Foster Wheeler’s Clean Energy Europe business
CERN is one of the world’s most prestigious science projects and sets very high standards for its suppliers.

“We have received excellent feedback about the quality of our work and have exceeded CERN’s expectations by delivering fully accredited results within five weeks on average, rather than the three months specified in the contracts.

“We aim to build on this developing relationship with CERN and offer a wider range of Amec Foster Wheeler services. This work complements our strategy to support ‘Big Science’ projects with engineering, project management and scientific consultancy, as well as the work we are doing at ITER, the world’s largest nuclear fusion project.
Greg Willetts, Consultancy Director of Amec Foster Wheeler’s Clean Energy Europe business

The LHC, a 17-mile ring of superconducting magnets which steer proton beams travelling at close to the speed of light, has enabled physicists and engineers to understand better how ordinary matter is constituted, for example by confirming the existence of the Higgs boson and discovering a new class of particles known as pentaquarks.

When protons deviate from the beam, they collide with magnets or other machine components and this produces a low level of induced activity in the materials. When some components are removed from the accelerators, radiochemical testing is required to ensure that they can be disposed of in the safest and most cost-effective way.

Amec Foster Wheeler’s radiochemical laboratories are some of the largest in the UK, carrying out independent testing for nuclear operators, research institutes, decommissioning contractors, contaminated land consultants, local authorities, regulators, water companies and defence establishments.

Notes to editors

Amec Foster Wheeler (www.amecfw.com) designs, delivers and maintains strategic and complex assets for its customers across the global energy and related sectors.

 

With pro-forma 2014 annualised scope revenues of £5.5 billion and over 40,000 people in more than 55 countries, the company operates across the whole of the oil and gas industry – from production through to refining, processing and distribution of derivative products – and in the mining, clean energy, power generation, pharma, environment and infrastructure markets.

 

Amec Foster Wheeler shares are publicly traded on the London Stock Exchange and its American Depositary Shares are traded on the New York Stock Exchange. Both trade under the ticker AMFW.

 

Forward-Looking Statements

This announcement contains statements which constitute “forward-looking statements”. Forward-looking statements include any statements related to the timing and success of contracts, and are generally identified by words such as “believe,” “expect,” “anticipate,” “intend,” “estimate,” “will,” “may,” “continue,” “should” and other similar expressions. Forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Amec Foster Wheeler, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking statements.

 

Amec Foster Wheeler does not undertake to update any of the forward-looking statements after this date to conform such statements to actual results, to reflect the occurrence of anticipated results or otherwise.